文献速递浆细胞疾病

新型药物时代多发性骨髓瘤患者的染色体1异常与生存

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.
PubMed 文献 · Blood Adv · 2020-01-01

基于美国Flatiron Health电子健康记录,纳入2011年1月至2018年3月新诊断且诊断后90天内行荧光原位杂交检测的多发性骨髓瘤患者3578例,其中844例(24%)记录有染色体1异常。染色体1异常与更差的总生存独立相关(校正风险比1.42,95%置信区间1.19-2.69,P<.001)。

要点

  • 3578例患者中844例(24%)记录有染色体1异常。
  • 染色体1异常患者中位总生存46.6个月,无染色体1异常者为70.1个月(对数秩检验P<.001)。
  • 染色体1异常与更差总生存独立相关(校正风险比1.42,95%置信区间1.19-2.69,P<.001)。

核心结论

  • 染色体1异常与更差的总生存相关,且独立于其他高危染色体异常,尽管新型治疗使用更多。
  • 作者认为,测试高危多发性骨髓瘤新型疗法的临床试验应纳入染色体1异常患者。

研究设计与样本

  • 使用美国Flatiron Health数据库电子健康记录,选取2011年1月至2018年3月新诊断的多发性骨髓瘤患者。
  • 纳入诊断后90天内行荧光原位杂交检测者,共3578例符合条件,其中844例(24%)记录有染色体1异常。
  • 采用Kaplan-Meier法比较总生存,分层对数秩检验以高危染色体异常存在与否为分层变量。
  • 采用Cox比例风险回归模型比较总生存,校正年龄、性别、分期、高危染色体异常和一线治疗类型。

主要发现

  • 染色体1异常患者较无染色体1异常者更常见R-ISS III期(18% vs 12%)、高危染色体异常(27% vs 14%)和蛋白酶体抑制剂联合免疫调节剂治疗(41% vs 34%)。
  • 染色体1异常患者中位总生存46.6个月,无染色体1异常者为70.1个月(对数秩检验P<.001)。
  • 染色体1异常与更差总生存独立相关(校正风险比1.42,95%置信区间1.19-2.69,P<.001)。
  • 年龄较大、较高R-ISS分期、高危染色体异常和免疫球蛋白A同种型也与更差总生存独立相关。

关键数值与推荐

  • 染色体1异常定义为荧光原位杂交检测记录的染色体1异常。
  • 高危染色体异常按修订版国际分期系统(R-ISS)定义,包括del(17p)、t(14;16)和t(4;14)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chromosome 1 abnormalities (C1As) are common genetic aberrations among patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As among a contemporary cohort of patients with MM in the United States. We used electronic health records from the Flatiron Health database to select patients newly diagnosed with MM from January 2011 to March 2018 who were tested using fluorescence in situ hybridization within 90 days of diagnosis. We characterized patients as having documented C1As or other high-risk chromosomal abnormalities (HRCAs) as defined by the Revised-International Staging System (R-ISS) such as del(17p), t(14;16), and t(4;14). We used Kaplan-Meier methods to compare overall survival (OS) of patients with or without C1As and stratified log-rank tests (with the presence of HRCAs as a stratifying variable). We used Cox proportional hazards regression models to compare OS, adjusting for age, sex, stage, HRCAs, and type of first-line therapy. Of 3578 eligible patients, 844 (24%) had documented C1As. Compared with patients without C1As, patients with C1As were more likely to have higher stage (R-ISS stage III; 18% vs 12%), to have HRCAs (27% vs 14%), and to receive combinations of proteasome inhibitors and immunomodulatory agents (41% vs 34%). Median OS was lower for patients with C1As (46.6 vs 70.1 months; log-rank P < .001). C1As were independently associated with worse OS (adjusted hazard ratio, 1.42; 95% confidence interval, 1.19-2.69; P < .001), as were older age, higher R-ISS stage, HRCAs, and immunoglobulin A isotype. C1As were associated with inferior OS, independent of other HRCAs, despite greater use of novel therapies. Clinical trials testing newer therapies for high-risk MM should incorporate patients with C1As.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Giri S, Huntington SF, Wang R, et al. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Adv. 2020. PMID: 32442299. doi:10.1182/bloodadvances.2019001425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。